68Ga-NODAGA-VEGF121 for in vivo imaging of VEGF receptor expression

Nuclear Medicine and Biology

Volumn 41, Issue 1, 2014, Pages 51-57

  Kang, Choong Mo ^a,b   Koo, Hyun Jung ^a   Choe, Yearn Seong ^a,b   Choi, Joon Young ^a   Lee, Kyung Han ^a,b   Kim, Byung Tae ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

68Ga NODAGA VEGF121; Angiogenesis; MicroPET; VEGFR

Indexed keywords

GALLIUM 1,4,7 TRIAZACYCLONONANE 1 GLUTARIC ACID 4,7 ACETIC ACID VASCULOTROPIN 121 GA 68; GALLIUM 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID BENZYL VASCULOTROPIN 121 GA 68; RADIOISOTOPE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; 1 (1,3 CARBOXYPROPYL) 4,7 CARBOXYMETHYL 1,4,7 TRIAZACYCLONONANE; 1-(1,3-CARBOXYPROPYL)-4,7-CARBOXYMETHYL-1,4,7-TRIAZACYCLONONANE; ACETIC ACID DERIVATIVE; CHELATING AGENT; DIAGNOSTIC AGENT; GALLIUM; SINGLE HETEROCYCLIC RINGS; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BINDING AFFINITY; BIOACCUMULATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG PURITY; DRUG RECEPTOR BINDING; DRUG STABILITY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HYDROPHILICITY; IMMUNOFLUORESCENCE; IN VIVO STUDY; ISOTOPE ANALYSIS; ISOTOPE LABELING; LIVER; MALE; MICRO-COMPUTED TOMOGRAPHY; MOLECULAR IMAGING; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; POSITRON EMISSION TOMOGRAPHY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RADIOACTIVITY; SPLEEN; SUBCUTANEOUS TISSUE TUMOR; (68)GA-NODAGA-VEGF(121); ANGIOGENESIS; ANIMAL; BLOOD; CHEMICAL PHENOMENA; CHEMISTRY; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; MICROPET; TUMOR CELL LINE; VEGFR;

(68)GA-NODAGA-VEGF(121); ANGIOGENESIS; MICROPET; VEGFR;

ACETATES; ANIMALS; CELL LINE, TUMOR; CHELATING AGENTS; DRUG STABILITY; GALLIUM RADIOISOTOPES; GENE EXPRESSION REGULATION; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MICE; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84888332362     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.09.005     Document Type: Article

References (24)

1. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
2. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004, 25:581-611.
3. Roodhart J.M., Langenberg M.H., Witteveen E., Voest E.E. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 2008, 3:132-143.
4. Wang H., Cai W., Chen K., Li Z.B., Kashefi A., He L., et al. A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur J Nucl Med Mol Imaging 2007, 34:2001-2010.
5. Yoshimoto M., Kinuya S., Kawashima A., Nishii R., Yokoyama K., Kawai K. Radioiodinated VEGF to image tumor angiogenesis in a LS180 tumor xenograft model. Nucl Med Biol 2006, 33:963-969.
6. Cai W., Chen K., Mohamedali K.A., Cao Q., Gambhir S.S., Rosenblum M.G., et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med 2006, 47:2048-2056.
7. 121 for the imaging of VEGF receptor expression in U87MG tumor xenograft models. Eur J Nucl Med Mol Imaging 2013, 40:198-206.
8. 64Cu-labeled vascular endothelial growth factor-121 positron emission tomography. Circulation 2008, 117:915-922.
9. Rodriguez-Porcel M., Cai W., Gheysens O., Willmann J.K., Chen K., Wang H., et al. Imaging of VEGF receptor in a rat myocardial infarction model using PET. J Nucl Med 2008, 49:667-673.
10. Cai W., Guzman R., Hsu A.R., Wang H., Chen K., Sun G., et al. Positron emission tomography imaging of poststroke angiogenesis. Stroke 2009, 40:270-277.
11. 68Ga-Labeled Radiopharmaceuticals for Positron Emission Tomography. Nucl Med Mol Imaging 2010, 44:233-240.
12. Shannon R.D. Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenides. Acta Crystallogr A 1976, 32:751-767.
13. Clarke E.T., Martell A.E. Stabilities of the Fe(III), Ga(III), and In(III) chelates of N, N', N'-triazacyclononanetriacetic acid. Inorganica Chim Acta 1991, 181:273-280.
14. 111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjugate Chem 2002, 13:530-541.
15. 68Ga-based PET-radiopharmaceuticals at room temperature. Bioconjugate Chem 2008, 19:569-573.
16. 3 integrin expression. Eur J Nucl Med Mol Imaging 2011, 38:1303-1312.
17. 18F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. Nucl Med Biol 2012, 39:777-784.
18. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001, 61:1781-1785.
19. 18F]galacto-RGD. PLoS Med 2005, 2:244-252.
20. 68Ga-NODAGA-folate conjugates. Mol Pharmaceutics 2012, 9:1136-1145.
21. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers. Nucl Med Biol 2012, 39:560-569.
22. 68Ga-labeled mannosylated human serum albumin (MSA) as a lymph node imaging agent for positron emission tomography. Nucl Med Biol 2011, 38:371-379.
23. 99mTc-labeled anti-Tac dsFv: effect of different acylating reagents. Nucl Med Biol 2002, 29:795-801.
24. Grünberg J., Jeger S., Sarko D., Dennler P., Zimmermann K., Mier W., et al. DOTA-functionalized polylysine: a high number of DOTA chelates positively influences the biodistribution of enzymatic conjugated anti-tumor antibody chCE7agl. Plos One 2013, 8:e60350.